8S00 の概要
| エントリーDOI | 10.2210/pdb8s00/pdb |
| 関連するPDBエントリー | 8r2a |
| 分子名称 | Lysine--tRNA ligase, LYSINE, 6-oxidanyl-~{N}-[(1-oxidanylcyclohexyl)methyl]-4-oxidanylidene-chromene-2-carboxamide, ... (6 entities in total) |
| 機能のキーワード | cryptosporidium, atp binding, ligase |
| 由来する生物種 | Cryptosporidium parvum Iowa |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 124552.01 |
| 構造登録者 | |
| 主引用文献 | Caldwell, N.,Peet, C.,Miller, P.,Colon, B.L.,Taylor, M.G.,Cocco, M.,Dawson, A.,Lukac, I.,Teixeira, J.E.,Robinson, L.,Frame, L.,Seizova, S.,Damerow, S.,Tamaki, F.,Post, J.,Riley, J.,Mutter, N.,Hanna, J.C.,Ferguson, L.,Hu, X.,Tinti, M.,Forte, B.,Norcross, N.R.,Campbell, P.S.,Svensen, N.,Caldwell, F.C.,Jansen, C.,Postis, V.,Read, K.D.,Huston, C.D.,Gilbert, I.H.,Baragana, B.,Pawlowic, M.C. Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy. Sci Transl Med, 16:eadm8631-eadm8631, 2024 Cited by PubMed Abstract: Cryptosporidiosis is a diarrheal disease caused by infection with spp. parasites and is a leading cause of death in malnourished children worldwide. The only approved treatment, nitazoxanide, has limited efficacy in this at-risk patient population. Additional safe therapeutics are urgently required to tackle this unmet medical need. However, the development of anti-cryptosporidial drugs is hindered by a lack of understanding of the optimal compound properties required to treat this gastrointestinal infection. To address this knowledge gap, a diverse set of potent lysyl-tRNA synthetase inhibitors was profiled to identify optimal physicochemical and pharmacokinetic properties required for efficacy in a chronic mouse model of infection. The results from this comprehensive study illustrated the importance of balancing solubility and permeability to achieve efficacy in vivo. Our results establish in vitro criteria for solubility and permeability that are predictive of compound efficacy in vivo to guide the optimization of anti-cryptosporidial drugs. Two compounds from chemically distinct series (DDD489 and DDD508) were identified as demonstrating superior efficacy and prioritized for further evaluation. Both compounds achieved marked parasite reduction in immunocompromised mouse models and a disease-relevant calf model of infection. On the basis of these promising data, these compounds have been selected for progression to preclinical safety studies, expanding the portfolio of potential treatments for this neglected infectious disease. PubMed: 39441903DOI: 10.1126/scitranslmed.adm8631 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
